Back to search results

Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Chronic Neuropathic Pain

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • HonorHealth, Scottsdale, Arizona, United States

    Study coordinator · neuroscienceresearch@honorhealth.com

  • University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

    Study coordinator · tricoordinators@uams.edu

  • The University of California, San Diego, La Jolla, California, United States

  • Johns Hopkins University, Baltimore, Maryland, United States

    Study coordinator · ayoyin2@jh.edu

  • Massachusetts General Hospital, Boston, Massachusetts, United States

    Study coordinator · imccarthy2@mgh.harvard.edu

  • Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States

  • Columbia University Irving Medical Center (CUIMC) and New York-Presbyterian Hospital (NYPH), New York, New York, United States

    Study coordinator · rf2632@cumc.columbia.edu

  • University of North Carolina Medical Center, Chapel Hill, North Carolina, United States

  • Vanderbilt University, Nashville, Tennessee, United States

  • University of Utah, Salt Lake City, Utah, United States

  • Virginia Commonwealth University, Richmond, Virginia, United States

    Study coordinator · swapna.keshamoni@vcuhealth.org
Study leads

  • Medical Monitor

    Study Director

    Sangamo Therapeutics Inc.

View source on ClinicalTrials.gov(opens in a new tab)